Symbols

OVID

Ovid Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

Revenue Beats Expectation

RSI Overbought

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About OVID

Ovid Therapeutics Inc.

A biopharmaceutical company that develops medicines designed to conquer epilepsies

Industry

Pharmaceutical

Established Date

04/01/2014

Listing Date

05/05/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ovidrx.com

Security Type

Common stock

Office address

441 Ninth Avenue, 14th Floor, New York, New York 10001

Business

Introduction

Ovid Therapeutics Inc., was incorporated on April 1, 2014 under the laws of the State of Delaware. The company is a biopharmaceutical company focused on developing small molecule drugs for brain diseases by targeting neuronal overexcitement. Its methods are designed to target fundamental biological targets in the central nervous system with a view to halting disease progression and alleviating symptoms.

Company Financials

EPS

OVID has released its 2025 Q4 earnings. EPS was reported at 0.06, versus the expected -0.11, beating expectations. The chart below visualizes how OVID has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

OVID has released its 2025 Q4 earnings report, with revenue of 718.00K, reflecting a YoY change of 844.74%, and net profit of 9.66M, showing a YoY change of 204.43%. The Sankey diagram below clearly presents OVID's revenue sources and cost distribution.